The respiratory tract infection treatment market comprises several drugs that effectively treat bacterial and viral infections affecting the respiratory tract such as the nasal passages, sinuses, pharynx, larynx, trachea, bronchi, and lungs. These drugs provide symptomatic relief from cough, fever, nasal congestion and other symptoms.
The global respiratory tract infection treatment market is estimated to be valued at US$ 103.19 Mn in 2024 and is expected to exhibit a CAGR of 7.1% over the forecast period 2024 to 2031.
Key Takeaways
Key players operating in the respiratory tract infection treatment are Abbott Laboratories, AstraZeneca, Plc, Abbvie Inc., Boehringer Ingelheim GmbH, Cipla Pharmaceutical Company, GlaxoSmithKline plc, Pfizer Inc., Merck & Co., Novartis AG, F. Hoffman La Roche Ltd, Sanofi, and Teva Pharmaceutical Industries Ltd. The increasing prevalence of respiratory infections owing to factors such as rising air pollution levels and changing demographics is expected to drive the demand for respiratory tract infection treatment drugs over the forecast period. Moreover, several market players are expanding their production facilities and distribution networks in developing regions of Asia Pacific and Latin America to tap the high growth potential in these untapped markets.
Market Key Trends
Antibiotic resistance has emerged as a serious threat to public health globally. Overuse and misuse of antibiotics has led to many disease-causing bacteria developing resistance to commonly used medicines. As a result, there is an increasing need for development of new and innovative drugs that can effectively treat antibiotic-resistant infections. Drug manufacturers are investing heavily in R&D to discover novel drug molecules that can overcome antibiotic resistance. They are also focusing on developing fixed-dose combination drugs and novel drug delivery systems to improve patient compliance and treatment outcomes in Respiratory Tract Infection Treatment Market Size.
Porter’s Analysis
Threat of new entrants: High capital requirements and economies of scale make it difficult for new players enter the market. There exist high costs associated with R&D for development of new drugs.
Bargaining power of buyers: The presence of a large number of established manufacturers and well recognized brands reduces the bargaining power of buyers.
Bargaining power of suppliers: Established pharmaceutical companies have a strong bargaining power over raw material suppliers and contract manufacturing organizations due to their large scale of operations.
Threat of new substitutes: Threat of new substitutes is moderate as there exist alternative treatment options available for respiratory tract infections.
Competitive rivalry: The respiratory tract infection treatment market features intense competition among leading manufacturers.
Geographical Regions
North America region currently accounts for the largest share of the global respiratory tract infection treatment market, mainly due to high per capita healthcare expenditure and growing prevalence of respiratory diseases.
The Asia Pacific region is poised to witness the fastest growth over the forecast period, with a CAGR of around 8%. Factors such as rising geriatric population, increasing urbanization, growing accessibility to healthcare services, and heightened awareness about respiratory diseases are fueling market expansion in Asia Pacific countries.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it